Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors

Abstract

Context: Gastric carcinoma (GC) is one of the most common cancers and the second most frequent cause of cancer-related deaths. Chemotherapy is an important therapeutic modality for GC. However, chemoresistance limited its success rate. Combination chemotherapy is often applied to prevent drug-induced resistance in cancers.Objective: The aim of this study is to evaluate whether the co-delivery of etoposide (ETP) and curcumin (CUR) with one nanoparticle can result in synergistic effects of both drugs. Methods: ETP-and CUR-loaded nanostructured lipid carriers (ETP-CUR-NLC) were prepared by the solvent injection technique. Their average size, zeta potential and drug loading were evaluated. Human gastric cancer cell lines (SGC7901 cells) were used for the testing of in vitro cytotoxicity studies, and in vivo anti-tumor efficacies of the carriers were evaluated on mice bearing SGC7901 cells xenografts.Results: ETP-CUR-NLC has a particle size of 114 nm, EPT-loading quantity of 83% and CURloading quantity of 82%. ETP-CUR-NLC displayed high cytotoxicity and enhanced antitumor activity in vitro and in vivo. Meanwhile, ETP-CUR-NLC displayed low cytotoxicity in normal tissues in vivo. Discussion and conclusion: The results demonstrate that ETP-CUR-NLC can achieve impressive anti-tumor activity. By combining CUR, an effective NF-kB inhibitor, with ETP, a powerful anticancer drug, in NLC, we could improve the therapeutic efficacy in cancer treatments. Our results showed that such co-loaded delivery systems could serve as a promising therapeutic approach to improve clinical outcomes against various malignancies.

Oxidative stress in female cancers

“…Thus, nanotechnology has emerged as an efficient alternative for curcumin incorporation into the tumor cells. In fact, new formulations with nanocarriers for co-delivery of curcumin with anti-neoplastic drugs have been tested using in vitro settings of cervical cancer cells [ 149 ]. In addition, formulations including other compounds such as epicatechin gallate, resveratrol and curcumin (TriCurin) have been analyzed with results showing a synergism in vitro and in vivo [ 150 , 151 ].…”

Dual Interactions of Amphiphilic Gelatin Copolymer and Nanocurcumin Improving the Delivery Efficiency of the Nanogels

“…Beside, curcumin possesses antioxidant, anti-inflammatory, antibacterial, antiviral and anticancer activities [34,35]. The phytochemical could generate a synergic activity with several kinds of anticancer drugs (such as Gemcitabine, Paclitaxel, Camptothecin, and Cisplatin) that was effective against the growth of many cancer cell lines [36,37,38,39,40]. However, Cur is lipophilic nature and poor aqueous solubility as well as low aqueous stability due to its fast metabolism leading to reduce the bioavailability of Cur.…”

Synergic Activity Against MCF-7 Breast Cancer Cell Growth of Nanocurcumin-Encapsulated and Cisplatin-Complexed Nanogels

“…Folate lipid nanoparticles could target into MCF7 cell line with the synergism of paclitaxel and curcumin [19]. Doxorubicin (DOX)/Cur nanoparticles inducing apoptosis in hepatocellular carcinoma, etoposide/Cur delivered by lipid nanostructures in gastric oncology regimens, camptothecin/Cur encapsulated in chitosan-modified polymeric nanoparticles to treat colon cancer have subsequently proved these trigger facilitated combined agents to be much more effective [20,21,22].…”